1480724-61-5

Vosoritide (BMN 111) is a modified recombinant CNP (C-type natriuretic peptide) analogue, binds to NPR-B (natriuretic peptide receptor type B) and reduces the activity of FGFR3 (fibroblast growth factor receptor 3). Vosoritide can be used in achondroplasia and dwarfism research[1][2][3].

The most common side effects of Vosoritide acetate include injection site reactions (such as swelling, redness, itching, or pain), vomiting, and decreased blood pressure.

[1] Duggan S. Vosoritide: First Approval. Drugs. 2021 Nov;81(17):2057-2062. DOI:10.1007/s40265-021-01623-w
[2] Shuhaibar LC, et al. Phosphatase inhibition by LB-100 enhances BMN-111 stimulation of bone growth. JCI Insight. 2021 May 10;6(9):e141426. DOI:10.1172/jci.insight.141426
[3] Lorget F, et al. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am J Hum Genet. 2012 Dec 7;91(6):1108-14. DOI:10.1016/j.ajhg.2012.10.014